These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32962993)

  • 21. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
    Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
    Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Topno RK; Lal CS; Das VNR; Das P
    Rev Soc Bras Med Trop; 2020; 54():e20200208. PubMed ID: 33338118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
    Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
    PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 25. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Katara GK; Verma S; Salotra P
    Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
    Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
    J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J; den Boer ML; Essink DR; Ritmeijer K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
    Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
    PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis.
    Mukhopadhyay D; Das NK; Roy S; Kundu S; Barbhuiya JN; Chatterjee M
    J Infect Dis; 2011 Nov; 204(9):1427-36. PubMed ID: 21933878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
    Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
    Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
    Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
    Ansari NA; Ramesh V; Salotra P
    Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
    Belay AD; Asafa Y; Mesure J; Davidson RN
    Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post Kala azar dermal leishmaniasis (PKDL) presenting with ulcerated chronic paronychia like lesion.
    Jha AK; Anand V; Mallik SK; Kumar P
    Kathmandu Univ Med J (KUMJ); 2012; 10(40):87-90. PubMed ID: 23575061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.